AbCellera Biologics (ABCL.US) saw a significant surge after positive results were reported from the mid-stage trial of the heat rash treatment drug ABCL635.

The Zhitong Finance App has learned that the stock price of the Canadian biotechnology company AbCellera Biologics (ABCL.US) rose nearly 35% on Monday, with an intraday increase of over 44%. The company stated that a potential drug for treating hot flash symptoms had met its primary endpoint in mid-stage clinical trials, showing efficacy.